Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 1.00 |
| ▸ | CPT1A | P50416 | 3/20 | 1.00 |
| ▸ | CPT1B | Q92523 | 3/20 | 1.00 |
| ▸ | CRAT | P43155 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teglicar SCHEMBL4450575 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| Teglicar SCHEMBL3687135 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| Teglicar SCHEMBL3685373 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| SCHEMBL2453804 | 0.93 | CPT2 (0.86) | CPT2CPT1ACPT1B | |
| SCHEMBL1579627 | 0.93 | CPT2 (0.86) | CPT2CPT1ACPT1B | |
| Formic Acid SCHEMBL2454365 | 0.89 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL6760579 | 0.88 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| Teglicar SCHEMBL13568151 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL12304907 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL12304895 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314144-B2 | Compounds having antitumor activity | DEFIANTE FARMACEUTICA, S.A. (PT) | 2012-11-20 | — | — | US | claimed |
| US-20100227791-A1 | Compounds Having Antitumor Activity | DEFIANTE FARMACEUTICA, S.A. (PT) | 2010-09-09 | — | — | US | claimed |
| EP-1713461-B1 | COMPOUNDS HAVING ANTITUMOR ACTIVITY | DEFIANTE FARMACEUTICA SA (PT) | 2010-08-11 | — | — | EP | claimed |
| US-RE40861-E1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | Sigma-Tau Industrie Farmaceutiche Reunite S.p.A. (IT) | 2009-07-21 | — | — | US | claimed |
| EP-1713461-A1 | COMPOUNDS HAVING ANTITUMOR ACTIVITY | DEFIANTE FARMACEUTICA LDA. (PT) | 2006-10-25 | — | — | EP | claimed |
| WO-2006041922-A2 | AGENTS AND METHODS FOR ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM | DARA BIOSCIENCES, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2005077354-A1 | COMPOUNDS HAVING ANTITUMOR ACTIVITY | DEFIANTE FARMACEUTICA LDA. (PT) | 2005-08-25 | — | — | WO | claimed |
| EP-1077925-B1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | SIGMA TAU IND FARMACEUTI (IT) | 2004-09-15 | — | — | EP | claimed |
| JP-2003513002-A | — | — | 2003-04-08 | — | — | JP | claimed |
| WO-1999059957-A9 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | SIGMA TAU IND FARMACEUTI (IT) | 2002-06-13 | — | — | WO | claimed |
| US-20020052348-A1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2002-05-02 | — | — | US | claimed |
| US-6369073-B1 | HYPERGLYCEMIA, DIABETES, HEART FAILURE, ISCHEMIA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-04-09 | — | — | US | claimed |
| EP-1077925-A1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059957-A1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-11-25 | — | — | WO | claimed |
| US-8314144-B2 | Compounds having antitumor activity | DEFIANTE FARMACEUTICA, S.A. (PT) | 2012-11-20 | — | — | US | disclosed |
| US-20100227791-A1 | Compounds Having Antitumor Activity | DEFIANTE FARMACEUTICA, S.A. (PT) | 2010-09-09 | — | — | US | disclosed |
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-6369073-B1 | HYPERGLYCEMIA, DIABETES, HEART FAILURE, ISCHEMIA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-04-09 | — | — | US | disclosed |
| EP-1077925-A1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059957-A1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052348-A1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | CPT1B, CPT1A, CPT2 | CPT2 3/4885CPT1A 2/4885CPT1B 1/4885 |
| US-20100227791-A1 | Compounds Having Antitumor Activity | GZMB, XPA, MKI67 | CPT2 1584/4885CPT1A 280/4885CPT1B 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.